The prognosis of patients with high MXD3 bladder cancer in the GEO database is poor, but the bladder patients in the MXD3 group have better prognosis after treatment with the immunotherapeutic point inhibitor. This evidence concerns the gene MXD3 and urinary bladder carcinoma.